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Abstract
Purpose
VVA is a common disease, with approximately 50% of all postmenopausal women having related symptoms. VVA has a
significant impact on the personal and sexual lives and on many aspects of women’s self-esteem and emotional well-being. It
is particularly frequent and severe in patients treated for BC, where it originates significant economic and social costs.
Given the lack of published evidence on this subject, a Delphi Panel was carried out to evaluate:
& The epidemiology of VVA and of its risk-factors/comorbidities in Italy
& The present standard of care and unmet medical needs
& The comparison between recent US epidemiological data and the Italian situation
& The health resources used in VVA BC
The burden of illnessDespite the considerable negative impact on quality of life, a disparity between the high prevalence of this
condition and the infrequent clinical diagnosis is documented in medical practice and in surveys. This inaccuracy is thought to be
primarily a consequence of patients’ unwillingness and/or reluctance to report symptoms in the clinical setting and of health-care
professional’s difficulty in approaching this sensitive topic during routine consultations.
Methods
A Delphi Panel methodology was used: a first round of written questionnaires, followed by a plenary meeting with a facilitator
and by two additional rounds of telephone interviews.
Results
The prevalence of the condition in Italy can be estimated in 115,000 cases out of 380,000 BC survivors.
The Panel confirmed that the epidemiological findings of a recent pharmacoeconomic analysis of a US claims database can be
applied to Italian patient population.
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The Panel confirmed also an estimate of 4.25 additional cases/100/yr of UTI (urinary tract infection) in VVABC patients (vs. a
non-VVA-matched population), of 3.68 additional cases of vulvovaginitis, of 6.97 cases of climacteric symptoms, and of 3.64
cases of bone and joint disorders.
As far as the resource use is concerned, in the VVA BC populations, 33.4 additional gynecological visits/100/year can be
expected, along with 22.8 additional cancer screenings, 7.07 additional outpatient visits and 5.04 screenings for HPV.
Conclusions
Even in Italy, a diagnosis of VVA, especially in a BC population, is associated with a relevant increase in the burden of illness and
social costs, compared to a control population matched for age without VVA. This is due essentially to an increase in comor-
bidities and resource utilization with the consequence that an adequate treatment could reduce the impact of the condition.
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Purpose
Vulvar and vaginal atrophy (VVA) is a relatively common
condition symptomatically affecting approximately 50% of
all postmenopausal women [1].
The earliest symptoms of VVA are decreased vaginal lu-
brication, followed by other vaginal and urinary symptoms
that may be exacerbated by superimposed infection, such as
burning, itching, bleeding, leucorrhea, dyspareunia, and dys-
uria. These symptoms usually appear within 4–5 years after
menopause [2–5].
Research has shown that the impact of VVA symptoms in
postmenopausal women is significant. The scale of the prob-
lem is growing as a result of greater longevity, leading to a
significant number of women spending more than one third of
their life in the postmenopausal state.
The disparity between the high prevalence of this condition
and the infrequent clinical diagnosis is documented in medical
practice and in surveys despite the considerable negative im-
pact on quality of life. This inaccuracy is thought to be pri-
marily a consequence of patients’ unwillingness and/or reluc-
tance to report symptoms in the clinical setting and health-care
professional’s (HCP) difficulty of approaching this sensitive
topic during routine consultations. The result of this
underdiagnosis is a chronic and progressive condition that
may not be addressed for long time and therefore more likely
to undergo disease progression when left untreated [6].
During the last decade, many cross-cultural studies, pre-
dominantly surveys, have been conducted on postmenopausal
women to gain new insight into the impact of VVA in current
postmenopausal populations from different geographic distri-
butions. These studies indicated that VVA symptoms have a
global negative effect on sexual health, satisfaction, and sexual
behavior, besides placing a relevant strain also on partners’
relationships [7]. Moreover, some surveys have clearly brought
to light the lack of women’s knowledge in this area [6].
VVA symptoms are associated with decrements in quality
of life that may be comparable to serious conditions such as
arthritis, chronic obstructive pulmonary disease, asthma, and
irritable bowel syndrome [1, 8].
These symptoms also feature prominently in women suf-
fering from premature iatrogenic menopause that is often
caused by cancer treatments. [9]. Moreover, local estrogen
therapy, which is considered the standard of care for VVA
symptoms, is contraindicated for some cancer survivors, leav-
ing patients with a limited number of options [9, 10].
Approximately 50–75% of breast cancer survivors suffer from
one or more VVA symptoms.
Aim of this research work, based on a Delphi Panel ap-
proach, was to assess the situation of VVA treatment in Italy,
with particular emphasis of the situation of patients with a
history of breast cancer (BC).
The Panel had also the objective to collect information on
the experience of participants with new treatments for VVA
(such as ospemifene) and on how these treatments are per-
ceived in terms of their capability to reduce symptoms asso-
ciated to VVA.
Methods
The Panel was organized and run according to the “Delphi
Panel” approach [11].
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A questionnaire was prepared and circulated by e-mail to
all participants, selected among the most relevant sites in Italy,
in the second half of November 2016. The complete question-
naire is available upon request.
The responses were collected and analyzed in the days
preceding the session, which took place in Milano on
November 24, 2016. The results of the analysis of the ques-
tionnaires were summarized in a series of tables and slides that
were presented during the sessions as a starting point for the
discussion.
Two additional rounds of follow-up interviews took place
in January 2017 and in July 2017. The final analyses were
completed in December 2018.
All the members of the Panel participated in the preparation
of the present work and are listed as authors.
Results
The responses given by sites, integrated by a follow-up survey
conducted during the months of December 2016 and January
2017, are detailed in Table 1.
The centers, considered together, covered the vast majority
of Italian regions, except for three areas (Valle D’Aosta,
Trentino, and Liguria).
According to the members, VVA is a widely diffused and
often underdiagnosed condition in Italy, with an estimated
number of over 115,000 BC survivors, sexually active and
with VVA [12].
This number, however, may increase in the future, due to
the present trend toward extending adjuvant treatment in high-
risk patients to more than 5 years.
The responses confirm that in patients with VVA without
BC, the mainstays of treatment are lubricants and systemic
and topical estrogens, while ospemifene is beginning to have
an important role.
The therapeutic options are considerably reduced in pa-
tients with a history of BC, in whom hormone replacement
therapy cannot be used.
Three sites reported the use of topical estrogens also in BC
survivors, based on the indications of recent guidelines that
would allow low dose topical estrogens also in patients with a
history of BC unresponsive to lubricants and moisturizers,
provided that they are not in treatment with aromatase inhib-
itors [13, 14].
Laser, whose efficacy has been very recently confirmed in
the general population of VVA patients by the VeLVET trial
[15], is viewed favorably by all Delphi Panel members but, in
their practices, it is seldom used for cost reasons.
The long-term efficacy and safety of this treatment, more-
over, has not yet been sufficiently demonstrated [16].
The responses and the following discussion confirm that
VVA is accompanied by an additional relevant burden of co-
morbidities and resource use, both in patients with and with-
out a history of BC.
During the discussion, the Panel reconsidered the frequen-
cy of the condition of “postmenopausal bleeding,” confirming
that there is a higher frequency of events in the VVA popula-
tion, especially in conjunction with sexual intercourse.
According to the members, this unexpected bleeding is a
cause of serious concern for patients and often originates visits
to the Emergency Room and a series of clinical tests/assess-
ments, to exclude the presence of an underlying neoplasm.
This subject was further elaborated during the two “follow-
up” interviews where the Panel members agreed on the series
of diagnostic and therapeutic procedures recommended after
an episode of bleeding.
According to the Delphi Panel members, patients with a
history of BC tend to suffer to a greater extent from the fol-
lowing conditions, some of which are related to VVA:
& Reduced quality of life
& Difficulties in sex life
& Depression and psychological problems
& Urinary tract infections (UTI) and dysuria
According to the members of the Delphi Panel, practically
all the comorbidities and additional resource uses seen in VVA
patients and related to this condition could be appropriately
addressed with the existing available therapies.
On the other hand, the sites reported a marked additional
unmet need in VVA patients with a history of BC, especially
in the following areas:
& Overall treatment of VVA
& Urinary tract infections and dysuria
& Postmenopausal bleeding
Table 1 Approximated patient populations followed at the participating sites (figures taken from patient records)
Site A Site B Site D Site E
Number of pats followed per year 3000 2500 1500 1200
With VVA 700 (23%) 1250 (50%) 750 (50%) 500 (40%)
With VVA and BC 70 (10%) 35 (3%) 110 (15%) 250 (50%)
Pats treated with ospemifene 50 60 30 50
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& Reduced Quality of Life
& Gynecological visits
During the discussion and the follow-up interviews, UTIs
were considered as clinically relevant problems because in
untreated VVA patients, there is a tendency to recurrence.
The responses to this question confirm that ospemifene is
perceived as an efficacious drug in all VVA patients.
There seems to be a tendency to privilege the use of
ospemifene, at least as a first line, in VVA patients with a
history of BC.
According to the Panel members, the main reason is the
cost which – since the drug is not reimbursed in Italy –may be
considered in some circumstances too high for patients who
do not have a history of BC.
This is also an indirect confirmation of the fact that the
overall situation of VVA patients with a history of BC is per-
ceived as more severe and less manageable than in the normal
population of these patients.
The additional burden of illness caused by VVA in patients
was evaluated in a semiquantitative manner by the Panel
members by comparing the results of a retrospective epidemi-
ological, record-based study performed on 313,382 US pa-
tients (data on file, follow-up of a research published in
[17]) with diagnosed VVA, with their clinical experience.
The study reported that the increase of the incidence
(expressed in additional cases per 100 patients per year) found
retrospectively for a series of events/comorbidities in patients
with VVA, with or without a history of breast cancer.
The members of the Panel were asked to evaluate the plau-
sibility of the causal relationship between the comorbidities/
events reported in the US study and their clinical experience
and to confirm or modify the expected number of additional
cases reported in the US analysis.
The responses of the sites are summarized in Table 2.
Discussion
This study started from an extended set of epidemiological
data originated in the US using a Health Claims database, a
very accurate and reliable source of information.
Due to the lack of epidemiological evidence for Italy and to
the difficulties of organizing an “ad hoc study,” a Delphi Panel
seemed an adequate preliminary approach to assess the situa-
tion in a semi-quantitative way and to guide future initiatives.
The Delphi Panel, which inherently reduces group-related
bias as much as possible, was used in fact to “bridge” the US
data and to evaluate its applicability to the Italian reality.
Some of the conclusions from the US study, in particular
those pertaining the urological and psychological implications
of VVA, were confirmed by our Panel. Others, quite expect-
edly, were modified or rejected as not relevant to the local
situation.
It can be stated, however, that the picture that emerged from
the Panel adequately represents the impact of VVA in BC
patients in Italy. The involved sites constitute a representative
sample of the Italian patient population and of the diagnostic
and treatment pathways applied inVVA patients with a history
of BC.
The results of Delphi Panel were able to shed some light on
the Italian situation and to confirm that also in Italy, VVA,
especially in BC patients, is a socially relevant condition.
Table 2 Estimated additional number of comorbidities/events (per 100 patients/year) associated with VVA by Delphi Panel components
Comorbidity/Event VVA newly diagnosed, non-BC patients
(additional cases/100 patients per year)
VVA newly diagnosed in patients with history of BC
(additional cases/100 patients per year)
Urinary tract infections 3.59 4.25
Urinary frequency 1.3 1.96
Gyn. visits 32.67 33.4
Vulvovaginitis 3.46 3.68
Gen. tract symptoms 2.43 3.38
Cancer screening 17.59 18.48
Postmenopausal bleeding 0 3.13
Psych. Unadjustment 10 10
Climacteric symptoms 6.48 6.97
Bone and cart. disorders 4.03 3.64
Cystocele 1.6 1.81
Mastopathy 1.54 0
Outpatient visits 1.88 2.53
Stress incontinence 1.4 1.98
Screen for HPV 3.26 2.96
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The results appear in line with several very recent papers
that emphasize the importance of VVA in general [3, 4,
18–20] and in BC patients [21] and confirm that the condition
still represents an unmet medical need [22].
Even though nothing can substitute an epidemiological
prospective study, which will be needed to obtain a definitive
and quantitative answer, the knowledge obtained through the
Delphi Panel will be very useful in guiding the choices of such
future study.
Conclusions
The Panel essentially confirmed that VVA is a diffused and
underdiagnosed condition.
In patients with a history of BC, signs and burden of illness of
VVA tend to be more severe, as well as more difficult to manage
due to the restricted number of therapeutic options [5, 23, 24].
Many of the conclusions of the US study on the comorbid-
ities and events associatedwith VVA can be applied also to the
Italian situation.
In particular, the Italian Panel agreed on the fact that gen-
itourinary problems appear more frequent in a VVA popula-
tion, including urinary tract infections, incontinence, and dys-
uria, all leading to a higher frequency of urological visits.
Genitourinary problems, especially infections and dysuria,
tend to be more severe in BC patients.
On the other hand, conditions reported in the US study,
such as postmenopausal bleeding, hematuria, uterine
leiomyoma and fibrocystic mastopathy were not considered
so important VVA comorbidities in Italy.
The most relevant consequences of VVA are in the “uro-
gynecological” and in the “psychological” domains, with a
relevant impact on the life of the patients.
The Panel was in fact unanimous in confirming that depres-
sion and the need for psychological counseling are more fre-
quent in VVA patients, along with difficulties in sex life and a
reduced quality of life. Also these problems are more severe in
VVA patients with a history of BC.
The diagnostic and therapeutic approach to VVA related
conditions is consistent throughout all represented sites and
involves also the use of a significant amount of NHS (National
Health System) resources.
Given the limited therapeutic options available, BC survi-
vors represent a relevant subpopulation of VVA patients that
could benefit from new therapeutic approaches.
In particular, vaginal laser has shown a beneficial effect in
treating VVA in BC survivors in the short term, but there is no
sufficient data on the long-term treatment.
Moreover, a new drug-like ospemifene has demonstrated
clinical safety on the breast tissue, and therefore it could be
indicated in women with previous history of breast cancer
who have completed treatment.
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